Screener
Oruka Therapeutics, Inc. ORKA Accrued Research And Development
Accrued Research And Development at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept orka:AccruedResearchAndDevelopment.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
FAQ
- What is Oruka Therapeutics, Inc.'s accrued research and development?
- Oruka Therapeutics, Inc. (ORKA) reported accrued research and development of $6.81M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s accrued research and development changed year-over-year?
- Oruka Therapeutics, Inc.'s accrued research and development increased by 56.1% year-over-year, from $4.36M to $6.81M.
- What does accrued research and development mean?
- This captures liabilities related to research and development activities that have been incurred but not yet invoiced or paid. It is a critical indicator of the company's ongoing R&D intensity and the near-term cash requirements for clinical and scientific programs.
Ask your AI about Oruka Therapeutics, Inc.'s accrued research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude